ESMO 2026 | PREDICT-IO identifies two-year endpoints predicting long-term IO benefit

The PREDICT-IO study really addresses this question for cancer incidence. immunotherapy, trying to understand who are the patients who have long-term benefit from the treatment, but looking at it at an early time point. And, you know, the challenge is that for most clinical trials, we want to have readouts around two years. Otherwise, we won’t be able to arrive at an answer in a meaningful way. And so what the PREDICT-IO study did was accumulate all this data from multiple clinical trials where the results were available to see what measures at that two-year endpoint actually reflected what happened at a later time point, like at five years. And so by studying this, they actually identified a few different parameters that could be measured at the two – year time point. One is the RMST endpoint, and the other one is the Cox Hazard Ratio that actually associated with ultimate benefit. And so from that perspective, it really lays the groundwork for us being able to use these early time points to better select drugs in the future. There are some caveats with the study, as there always are. And I think, you know, the opportunity is really now that they’ve accumulated all this data to actually apply some other tests and see if others might actually perform even better than what they’ve identified.